November 22, 2016
When sofosbuvir (Sovaldi) was approved in 2013, it was celebrated for high cure rates, but it wasn't perfect for every patient with hepatitis C. By 2016, a slew of new medicines closed the gap for the vast majority of those tough-to-treat patients, including patients with any genotype or fibrosis level, or coinfection with HIV.
Despite the diversity of new direct-acting antivirals (DAAs), a tiny number of patients are still left behind. These include patients with genotype 3 infection plus liver damage, patients who have failed prior treatment or developed resistance and patients with decompensated cirrhosis.
At the recent Liver Meeting in Boston, Nancy Reau, M.D., section chief, Hepatology, Rush University Medical Center, presented a summary of soon-to-be-approved drugs that should work for this "handful" of groups.
Credit: ribkhan for iStock via Thinkstock.
Sony Salzman is a freelance journalist reporting on health care and medicine, who has won awards in both narrative writing and radio journalism. Follow Salzman on Twitter: @sonysalz.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|